Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:abuseDeterrent |
yes
|
| gptkbp:activeIngredient |
gptkb:oxycodone
gptkb:naloxone |
| gptkbp:approvalYear |
2014
|
| gptkbp:ATCCode |
N02AA55
|
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:form |
extended-release tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Targiniq ER
|
| gptkbp:indication |
pain management
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Purdue_Pharma
|
| gptkbp:mechanismOfAction |
mu-opioid receptor agonist (oxycodone)
opioid receptor antagonist (naloxone) |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:bfsParent |
gptkb:Purdue_Pharma
|
| gptkbp:bfsLayer |
6
|